Mechanisms Underlying the Contribution of Type 1 Diabetes Disease-associated Variants (R01 Clinical Trial Not Allowed) | RFA DK 19 020

Opportunity Information: Apply for RFA DK 19 020

The National Institutes of Health (NIH) released this grant opportunity, RFA-DK-19-020, titled "Mechanisms Underlying the Contribution of Type 1 Diabetes Disease-associated Variants (R01 Clinical Trial Not Allowed)," to push the field beyond statistical genetic associations and toward clear biological explanations for why particular DNA variants change a person s risk of developing type 1 diabetes (T1D). Over the last several years, genome-wide association studies (GWAS) and related genomic approaches have identified many genetic variants linked to higher risk or, in some cases, protection from T1D. The core problem is that these studies often point to broad genomic regions rather than pinpointing the exact causal variant, the relevant cell type, the target gene(s), or the molecular pathway that ultimately alters immune function or beta cell vulnerability. This FOA is designed to fund large, complex, multidisciplinary functional genomics projects that can systematically resolve those open questions and translate association signals into mechanistic insight.

The scientific goal is to identify, across all known T1D risk-associated loci, which variants are truly causal, what genomic elements they disrupt or modify (such as enhancers, promoters, or other regulatory features), and which downstream "effector" transcripts and pathways are responsible for driving disease-related biology. The FOA emphasizes an end-to-end strategy: first, fine-mapping and functional approaches to identify causal variants; second, connecting those variants to the genes and transcripts they regulate in the relevant contexts; third, experimentally verifying the roles of those effector transcripts; and finally, integrating results into network models that explain how multiple genes and regulatory elements work together to influence T1D. The expectation is that successful projects will not only generate lists of variants and genes, but will also deliver coherent mechanistic models that can be tested and refined, helping the community understand the molecular chain of events from genetic variation to altered immune responses or beta cell outcomes.

The opportunity uses the R01 grant mechanism and is explicitly "Clinical Trial Not Allowed," meaning the focus is on mechanistic, functional, and computational biology rather than interventional studies in human participants. In practical terms, projects are expected to be large-scale and integrative, which can include coordinated experimental and computational work, multi-omic analyses, gene regulation studies, genome editing validation, and systems biology modeling. The FOA encourages applications both from integrative teams and from individual investigators who can credibly execute complex functional genomics work, reflecting the reality that mapping variants to function often requires expertise spanning statistical genetics, immunology, molecular biology, genomics, bioinformatics, and network modeling.

NIH highlights why this work matters: clarifying causal variants and mechanisms could unlock more reliable biomarkers for identifying at-risk individuals, improve screening strategies, inform prevention approaches, and support rational drug design by pointing to concrete molecular targets rather than broad genomic regions. In addition, better-defined molecular networks can guide more tailored therapies, because they can reveal which pathways are most relevant for specific genetic backgrounds or disease subtypes. In short, the intended payoff is a more actionable understanding of T1D biology, grounded in experimentally validated links between genetic variation and cellular function.

From an administrative standpoint, the award is categorized as a discretionary grant in the Health (and Food and Nutrition/Health) activity area, listed under CFDA 93.847. The posted award ceiling is $850,000, and the original closing date listed is 2020-06-26. The eligible applicant pool is broad and includes many types of domestic U.S. organizations such as state, county, and city governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status; for-profit organizations (other than small businesses); and small businesses. The announcement also explicitly calls out additional eligible groups and institution types, including Alaska Native and Native Hawaiian Serving Institutions, AANAPISISs, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, regional organizations, and non-U.S. entities (foreign organizations). This wide eligibility reflects the FOA s interest in mobilizing the best available expertise and resources across sectors and geographies to tackle the complexity of T1D functional genomics.

Overall, this FOA is aimed at closing the gap between genetic discovery and biological mechanism in type 1 diabetes by funding ambitious functional genomics projects that can systematically identify causal variants, connect them to effector genes and transcripts, validate those downstream effects, and integrate findings into network-level explanations. The longer-term intent is to turn genetic associations into concrete biological knowledge that can eventually support better prediction, prevention, and treatment strategies for T1D.

• The National Institutes of Health in the food and nutrition, health sector is offering a public funding opportunity titled "Mechanisms Underlying the Contribution of Type 1 Diabetes Disease-associated Variants (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847.
• This funding opportunity was created on 2019-11-06.
• Applicants must submit their applications by 2020-06-26. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $850,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA DK 19 020

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: